相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
Cheng Chen et al.
ACTA PHARMACOLOGICA SINICA (2021)
B7-H3: An Attractive Target for Antibody-based Immunotherapy
Filippos Kontos et al.
CLINICAL CANCER RESEARCH (2021)
TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT
Er Nie et al.
NEURO-ONCOLOGY (2021)
Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib
Olivia Campagne et al.
CLINICAL PHARMACOKINETICS (2021)
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
Wantao Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
Nathan D. Mathewson et al.
CELL (2021)
LAG-3 expression in the inflammatory microenvironment of glioma
Maximilian J. Mair et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential
Vanaja Konduri et al.
FRONTIERS IN IMMUNOLOGY (2021)
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
Alexander H. Lee et al.
NATURE COMMUNICATIONS (2021)
Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
Tereza Andreou et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis
Amina Ghouzlani et al.
FRONTIERS IN ONCOLOGY (2021)
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Liz J. Hernandez Borrero et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma
Minling Gao et al.
CANCER RESEARCH (2021)
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
Dorothee Gramatzki et al.
EUROPEAN JOURNAL OF CANCER (2021)
Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system
Natalia N. Ferreira et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2021)
Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage
Alexandra M. Amen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas
Mengli Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
Lijie Zhai et al.
CLINICAL CANCER RESEARCH (2021)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Hao Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Bianca-Maria Marin et al.
NEURO-ONCOLOGY (2021)
Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion
Daniel J. Shepherd et al.
ONCOLOGIST (2021)
A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint
Xiaohan Zhou et al.
FRONTIERS IN IMMUNOLOGY (2021)
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
Johnny Duerinck et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Pharmacological Approaches in Neurofibromatosis Type 1-Associated Nervous System Tumors
Omar Rabab'h et al.
CANCERS (2021)
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
Xanthene Miles et al.
FRONTIERS IN ONCOLOGY (2021)
Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
John Choi et al.
ONCOIMMUNOLOGY (2021)
IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification
Giulia Berzero et al.
NEURO-ONCOLOGY (2021)
H-Ferritin nanoparticle-mediated delivery of antibodies across a BBB in vitro model for treatment of brain malignancies
Maria Antonietta Rizzuto et al.
BIOMATERIALS SCIENCE (2021)
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial
Theophilos Tzaridis et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
W. Larry Gluck et al.
INVESTIGATIONAL NEW DRUGS (2020)
Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach
J. H. Azambuja et al.
MOLECULAR NEUROBIOLOGY (2020)
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Martin van den Bent et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability
Liao XueMei et al.
CANCER SCIENCE (2020)
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan et al.
DRUG RESISTANCE UPDATES (2020)
PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status
Allison M. Martin et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2020)
Programmable base editing of mutated TERT promoter inhibits brain tumour growth
Xinjian Li et al.
NATURE CELL BIOLOGY (2020)
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Sangeeta Goswami et al.
NATURE MEDICINE (2020)
A Clickable Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
Sudhir Raghavan et al.
CANCERS (2020)
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
Nicholas F. Brown et al.
BMC CANCER (2020)
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
Eudocia Q. Lee et al.
CANCER (2020)
Blockade of CD73 delays glioblastoma growth by modulating the immune environment
J. H. Azambuja et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Lower Grade Gliomas
Gilbert Youssef et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2020)
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424
Barbara J. Fisher et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
Xiaozheng Xu et al.
JOURNAL OF CELL BIOLOGY (2020)
Molecular markers and targeted therapy in pediatric low-grade glioma
Peter de Blank et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
Christina A. von Roemeling et al.
NATURE COMMUNICATIONS (2020)
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Thomas J. Kaley et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
Di Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Carmen Balana et al.
NEURO-ONCOLOGY (2020)
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study
Nicole J. Ullrich et al.
NEURO-ONCOLOGY (2020)
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2020)
Epithelioid glioblastoma with microglia features: potential for novel therapy
Nami Nakagomi et al.
BRAIN PATHOLOGY (2020)
Glioblastomas harboring gene fusions detected by next-generation sequencing
Ha Young Woo et al.
BRAIN TUMOR PATHOLOGY (2020)
Management of glioblastoma: State of the art and future directions
Aaron C. Tan et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
How did lomustine become standard of care in recurrent glioblastoma?
Michael Weller et al.
CANCER TREATMENT REVIEWS (2020)
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Lijie Zhai et al.
FRONTIERS IN IMMUNOLOGY (2020)
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration
Martina Ott et al.
JCI INSIGHT (2020)
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Mark Rosenthal et al.
ESMO OPEN (2020)
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Patrick Yung Wen et al.
ESMO OPEN (2020)
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Xing Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Discovery of AB680: A Potent and Selective Inhibitor of CD73
Kenneth Lawson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Retrospective analysis of combination carboplatin and vinblastine for pediatric low-grade glioma
Anandani Nellan et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
J-S. Frenel et al.
ANNALS OF ONCOLOGY (2020)
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
Barbara Oldrini et al.
NATURE COMMUNICATIONS (2020)
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Xin Cui et al.
ELIFE (2020)
Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
Christophe Lallemand et al.
FRONTIERS IN IMMUNOLOGY (2020)
LAG-3: from molecular functions to clinical applications
Takumi Maruhashi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
HGG-48. ROS1 INHIBITOR ENTRECTINIB USE IN RELAPSE/REFRACTORY INFANTILE GLIOBLASTOMA WITH POSITIVE ROS1 FUSION - A CASE REPORT WITH PROMISING RESPONSE
Dennis Tak-Loi Ku et al.
NEURO-ONCOLOGY (2020)
A phase 0 analysis of ixazomib in patients with glioblastoma
Joseph Quillin et al.
MOLECULAR AND CLINICAL ONCOLOGY (2020)
Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib
Musa Alharbi et al.
JCO PRECISION ONCOLOGY (2020)
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors
Meijia Yang et al.
THERANOSTICS (2020)
TIM3 comes of age as an inhibitory receptor
Yochai Wolf et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway
Lisha Du et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Genomic and immunologic correlates of LAG-3 expression in cancer
Anshuman Panda et al.
ONCOIMMUNOLOGY (2020)
Safety and efficacy of depatuxizumab mafodotin plus temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2019)
CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway
Xuejian Liu et al.
ONCOLOGY RESEARCH (2019)
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
Alireza Mansouri et al.
NEURO-ONCOLOGY (2019)
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2019)
Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases
Kiyong Na et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
Jiayi Huang et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma
Jingwen Zhang et al.
LABORATORY INVESTIGATION (2019)
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Kurt A. Schalper et al.
NATURE MEDICINE (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
Aida Karachi et al.
NEURO-ONCOLOGY (2019)
Deciphering the complex role of thrombospondin-1 in glioblastoma development
Thomas Daubon et al.
NATURE COMMUNICATIONS (2019)
Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts
Masamichi Takahashi et al.
CANCER SCIENCE (2019)
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Xuejiao Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
Jason Fangusaro et al.
LANCET ONCOLOGY (2019)
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Maisa C. Takenaka et al.
NATURE NEUROSCIENCE (2019)
A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
An-Chi Tien et al.
CLINICAL CANCER RESEARCH (2019)
MET in glioma: signaling pathways and targeted therapies
Fangling Cheng et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Phase II study of Dovitinib in recurrent glioblastoma
Mayur Sharma et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma
Andrew B. Lassman et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
Javier Celis-Gutierrez et al.
CELL REPORTS (2019)
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival
Mohummad Aminur Rahman et al.
BRITISH JOURNAL OF CANCER (2019)
Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Alexandros Papachristodoulou et al.
CLINICAL CANCER RESEARCH (2019)
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma
Eudocia Q. Lee et al.
CANCER MEDICINE (2019)
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
Dean Nehama et al.
EBIOMEDICINE (2019)
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
Karisa C. Schreck et al.
CANCERS (2019)
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
John D. Hainsworth et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma
Todd W. Miller et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016
Roberta Ruda et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2019)
Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma
Stefano Indraccolo et al.
CLINICAL CANCER RESEARCH (2019)
A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
Sebastien Perreault et al.
BMC CANCER (2019)
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Darren R. Hargrave et al.
CLINICAL CANCER RESEARCH (2019)
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
Gregor Hutter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
Timothy F. Cloughesy et al.
NEURO-ONCOLOGY (2018)
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2018)
CD70, a novel target of CAR T-cell therapy for gliomas
Linchun Jin et al.
NEURO-ONCOLOGY (2018)
Blocking the CD47-SIRP alpha axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells
Feng Li et al.
ONCOIMMUNOLOGY (2018)
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
Catherine A. Sabatos-Peyton et al.
ONCOIMMUNOLOGY (2018)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
Pierre Bady et al.
ACTA NEUROPATHOLOGICA (2018)
Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma
Zhiliang Wang et al.
CANCER SCIENCE (2018)
Disrupting CD47-SIRP alpha axis alone or combined with autophagy depletion for the therapy of glioblastoma
Xuyao Zhang et al.
CARCINOGENESIS (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma
Erik Ladomersky et al.
CLINICAL CANCER RESEARCH (2018)
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
Nader Sanai et al.
CLINICAL CANCER RESEARCH (2018)
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment
Xiao-Tang Kong et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma
Jiayi Huang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Sherise D. Ferguson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)
Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors
Karisa C. Schreck et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
Mary Lou Affronti et al.
ONCOLOGIST (2018)
A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA
Bum-Sup Jang et al.
RADIOTHERAPY AND ONCOLOGY (2018)
Structural absorption by barbule microstructures of super black bird of paradise feathers
Dakota E. McCoy et al.
NATURE COMMUNICATIONS (2018)
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide An Analysis From the NRG Oncology/RTOG 0424 Trial
Erica H. Bell et al.
JAMA ONCOLOGY (2018)
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
Lea Kristin Roever et al.
EBIOMEDICINE (2018)
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
Sarah Harris-Bookman et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Rimas V. Lukas et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
Jennie W. Taylor et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406)
M van den Bent et al.
NEURO-ONCOLOGY (2018)
Dendritic cell vaccines for high-grade gliomas
Matthew E. Eagles et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
Michael W. Ronellenfitsch et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
Thomas Kaley et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase 2 and Biomarker Study of Trebananib, an Angiopoietin-Blocking Peptibody, With and Without Bevacizumab for Patients With Recurrent Glioblastoma
David A. Reardon et al.
CANCER (2018)
The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy
Sarah L. Buchan et al.
BLOOD (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma
Jayashree Kalpathy-Cramer et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Tim-3 and its role in regulating anti-tumor immunity
Madhumita Das et al.
IMMUNOLOGICAL REVIEWS (2017)
Potential targeting of B7-H4 for the treatment of cancer
Joseph R. Podojil et al.
IMMUNOLOGICAL REVIEWS (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
CNS Tumors in Neurofibromatosis
Jian Campian et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses
Timothy Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
Lakshmi Nayak et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Susana Inoges et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller et al.
LANCET ONCOLOGY (2017)
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Hua-fu Zhao et al.
MOLECULAR CANCER (2017)
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Juan Manuel Sepulveda-Sanchez et al.
NEURO-ONCOLOGY (2017)
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
Anuradha Banerjee et al.
NEURO-ONCOLOGY (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
Sharareh Gholamin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
Guanzhang Li et al.
ONCOIMMUNOLOGY (2017)
Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment
Anna H. Turaj et al.
CANCER CELL (2017)
Targeting immunosuppressive adenosine in cancer
D. Vijayan et al.
NATURE REVIEWS CANCER (2017)
Probing the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Pathway in Gliomas: A Phase 2 Study of Everolimus for Recurrent Adult Low-Grade Gliomas
Michael Wahl et al.
CANCER (2017)
Surgical resection versus watchful waiting in low-grade gliomas
A. S. Jakola et al.
ANNALS OF ONCOLOGY (2017)
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A. Batich et al.
CLINICAL CANCER RESEARCH (2017)
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature
Steven Seaman et al.
CANCER CELL (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group
Joann L. Ater et al.
CANCER (2016)
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion
Stephanie Du Four et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
Deepak Mittal et al.
CANCER RESEARCH (2016)
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Lale Erdem-Eraslan et al.
CANCER RESEARCH (2016)
Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma
William T. Curry et al.
CLINICAL CANCER RESEARCH (2016)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2016)
RB1: a prototype tumor suppressor and an enigma
Nicholas J. Dyson
GENES & DEVELOPMENT (2016)
Phase II Weekly Vinblastine for Chemotherapy-Naive Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study
Alvaro Lassaletta et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immune phenotypes predict survival in patients with glioblastoma multiforme
Haouraa Mostafa et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma
Giovanni Brigliadori et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial
Mustafa Khasraw et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Deborah T. Blumenthal et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model
Mitsuto Hanihara et al.
JOURNAL OF NEUROSURGERY (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Jaap C. Reijneveld et al.
LANCET ONCOLOGY (2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G. Baumert et al.
LANCET ONCOLOGY (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Tor-Christian Aase Johannessen et al.
MOLECULAR CANCER RESEARCH (2016)
The role of microglia and macrophages in glioma maintenance and progression
Dolores Hambardzumyan et al.
NATURE NEUROSCIENCE (2016)
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A. Brandes et al.
NEURO-ONCOLOGY (2016)
Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo
Emese Szabo et al.
NEURO-ONCOLOGY (2016)
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Daniela F. Quail et al.
SCIENCE (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns et al.
CANCER DISCOVERY (2016)
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
Michael Weller et al.
ONCOTARGET (2016)
Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Michael Zhang et al.
PLOS ONE (2016)
Immunoregulation by members of the TGFβ superfamily
WanJun Chen et al.
NATURE REVIEWS IMMUNOLOGY (2016)
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
Adriana Olar et al.
ACTA NEUROPATHOLOGICA (2015)
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality
Rachelle G. Veenstra et al.
BLOOD (2015)
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma
Matthew Z. Sun et al.
JOURNAL OF NEUROSURGERY (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R. Gerstner et al.
NEURO-ONCOLOGY (2015)
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster et al.
NEURO-ONCOLOGY (2015)
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
L. Burt Nabors et al.
NEURO-ONCOLOGY (2015)
Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
S. Brandner et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Radiation Therapy Oncology Group 9802: Controversy or Consensus in the Treatment of Newly Diagnosed Low-Grade Glioma?
Nadia N. Laack et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
Daniel J. Ma et al.
NEURO-ONCOLOGY (2015)
OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Frank B. Furnari et al.
NATURE REVIEWS CANCER (2015)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline
Feng Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity
Dallas B. Flies et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression
Gunter Eisele et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas
Matthias A. Karajannis et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)lL17(+) response
Michael R. Olin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A phase 1 study of repeat radiation, minocycline, and bevacizumab in patients with recurrent glioma (RAMBO).
Adam Louis Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience
Quintino Giorgio D'Alessandris et al.
ACTA NEUROCHIRURGICA (2013)
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Einar Osland Vik-Mo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Bertrand Allard et al.
CLINICAL CANCER RESEARCH (2013)
A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2013)
5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells
Claudia Quezada et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection
Johannes vom Berg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients
Robert M. Prins et al.
JOURNAL OF IMMUNOTHERAPY (2013)
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck et al.
NATURE MEDICINE (2013)
Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas
Shuo Xu et al.
NEURO-ONCOLOGY (2013)
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group
Tobey J. MacDonald et al.
NEURO-ONCOLOGY (2013)
A Feasibility and Efficacy Study of Rapamycin and Erlotinib for Recurrent Pediatric Low-Grade Glioma (LGG)
Michal Yalon et al.
PEDIATRIC BLOOD & CANCER (2013)
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T. Batchelor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
Diane Tseng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TERT Promoter Mutations in Familial and Sporadic Melanoma
Susanne Horn et al.
SCIENCE (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
B7-H4 expression is elevated in human U251 glioma stem-like cells and is inducible in monocytes cultured with U251 stem-like cell conditioned medium
Lian-Jie Mo et al.
CHINESE JOURNAL OF CANCER (2013)
Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
A. Gregory Sorensen et al.
CANCER RESEARCH (2012)
Targeting of a Conformationally Exposed, Tumor-Specific Epitope of EGFR as a Strategy for Cancer Therapy
Hui K. Gan et al.
CANCER RESEARCH (2012)
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Christina Claus et al.
CANCER RESEARCH (2012)
Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Dieter Lemke et al.
CLINICAL CANCER RESEARCH (2012)
Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas
Asgeir S. Jakola et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling
Salvatore J. Coniglio et al.
MOLECULAR MEDICINE (2012)
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
Bret B. Friday et al.
NEURO-ONCOLOGY (2012)
Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia
Valerie L. Jacobs et al.
NEURO-ONCOLOGY (2012)
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
Qian Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Devendra Singh et al.
SCIENCE (2012)
Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
John F. de Groot et al.
CLINICAL CANCER RESEARCH (2011)
Activation of CD47 Receptors Causes Proliferation of Human Astrocytoma but Not Normal Astrocytes via an Akt-Dependent Pathway
Emilie Sick et al.
GLIA (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Hideho Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Li Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Camilo E. Fadul et al.
JOURNAL OF IMMUNOTHERAPY (2011)
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report
Toshihiko Wakabayashi et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Targeted therapy for high-grade glioma with the TGF-beta 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study
U. Bogdahn et al.
NEURO-ONCOLOGY (2011)
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2011)
Characteristics of the Alternative Phenotype of Microglia/Macrophages and its Modulation in Experimental Gliomas
Konrad Gabrusiewicz et al.
PLOS ONE (2011)
A Phase 2 Trial of Single-Agent Bevacizumab Given in an Every-3-Week Schedule for Patients With Recurrent High-Grade Gliomas
Jeffrey J. Raizer et al.
CANCER (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors
Brian J. Scott et al.
NEURO-ONCOLOGY (2010)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2010)
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma
Sandeep Kunwar et al.
NEURO-ONCOLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
M. D. Groves et al.
BRITISH JOURNAL OF CANCER (2009)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction
Judith Leitner et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
Tom Mikkelsen et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography
Oliver Schnell et al.
NEURO-ONCOLOGY (2009)
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
Christopher J. Wheeler et al.
CANCER RESEARCH (2008)
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012
Tobey J. MacDonald et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells
Yu Yao et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas
Y. Komohara et al.
JOURNAL OF PATHOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
A combination of IFN-β and temozolomide in human glioma xenograft models:: implication of p53-mediated MGMT downregulation
Atsushi Natsume et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
Hideho Okada et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1
Patrick Roth et al.
CANCER RESEARCH (2007)
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group
Sandeep Kunwar et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma
Johannes E. A. Wolff et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
S. Farzana Hussain et al.
NEURO-ONCOLOGY (2006)
IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide
A Natsume et al.
CANCER RESEARCH (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
CD27 and CD70 in T cell and B cell activation
J Borst et al.
CURRENT OPINION IN IMMUNOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator
LC Gonzalez et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator
JR Sedy et al.
NATURE IMMUNOLOGY (2005)
Cytokines in cancer pathogenesis and cancer therapy
G Dranoff
NATURE REVIEWS CANCER (2004)
CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation
YL Xiao et al.
JOURNAL OF IMMUNOLOGY (2004)
Expression and activation of signal regulatory protein alpha on astrocytomas
TT Chen et al.
CANCER RESEARCH (2004)
Protein degradation and protection against misfolded or damaged proteins
AL Goldberg
NATURE (2003)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity
GL Sica et al.
IMMUNITY (2003)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Characterization of mouse and human B7-H3 genes
MY Sun et al.
JOURNAL OF IMMUNOLOGY (2002)
CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors
J Held-Feindt et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L Monney et al.
NATURE (2002)
Integrin-associated protein (CD47) and its ligands
EJ Brown et al.
TRENDS IN CELL BIOLOGY (2001)
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production
AI Chapoval et al.
NATURE IMMUNOLOGY (2001)
分享论文
